Clinical Trial

A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting

Study acronym: GURU
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches) using muscoloskeletal ultrasound (MSUS) in a real-world setting.
Protocol Amendment History 1 change
minor Completion pushed: 2027-09-30 -> 2028-06-30 2026-08-01
Trial Details
NCT Number NCT07220824
Lead Sponsor Janssen Research & Development, LLC
Conditions Arthritis, Psoriatic
Enrollment 200 participants
Start Date 2025-12-04
Primary Completion 2027-07-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-31